Background: The survival benefit of heart transplantation (HT) compared to current optimal medical therapy (OMT) or Ventricular Assist Device (VAD) implantation in heart failure has never been assessed directly. Methods: We created a decision analytic model that simulates a randomized clinical trial of OMT versus HT versus VAD for New York Heart Association (NYHA) class I-IV heart failure (HF). The model simulates average life expectancy. The following assumptions were made for OMT annual mortality: class I confers no excess mortality; class II and III mortalities are based on Sudden Cardiac Death in Heart Failure Study (SCD-HeFT) and assumed to be 4.4% and 13.2% per patient year of follow-up respectively. Class IV annualized mortality for OMT is based on Scientific Registry of Transplant Recipients(SRTR) data for Status 1A and 1B patients (class 4A and 4B) listed for transplantation and assumed to be 53.6% for status 1A and 32.6% for Status 1B. HT mortality rates were based on survival curves for HT 1982e2001 from the International Society of Heart and Lung Transplantation. VAD mortality was 41% per year based on information from later enrolled Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure REMATCH trial patients. Results: Destination therapy for LVAD had an expected survival of 17 months regardless of preceding heart failure class and was not favored over OMT or HT for any class. For Classes I and II, OMT was the favored strategy with gains over HT of 108 months and 29 months respectively and with gains over LVAD of 211 months and 128 months respectively. For Classes III, IV-A and IV-B, HT was favored with gains over OMT of 31, 61 and 54 months, respectively and gains over LVAD of 58, 8 and 25 months, respectively. For Class IV-A, mortality following LVAD placement would have to decrease by 33% (to 0.028 monthly) for LVAD to equal OMT. For Class IV-B, mortality following LVAD placement would have to decrease by 67% to 0.014 monthly for LVAD to equal OMT. Conclusions: Our model predicts that currently, OMT is superior to HT or VAD for classes I & II, but HT is superior to both OMT and VAD for class III and IV. However, future advances in OMT, VAD or HT may change the relative benefits of these treatment modalities.
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Results/Discussion: Each patient's VAD parameters exhibited a distinct daily periodical pattern corresponding to a circadian cycle. VAD flow fluctuated by an average of 62 L/min corresponding with a decrease in flow demand typically observed in the evening hours followed by an increase in flow during a patient's waking hours. Conclusion: HeartWare Ò LVAS parameters may be used to extract individual circadian rhythms of each patient by analyzing the daily estimated flow. This data contains distinct periodical patterns related to each patient as reflected in daily fluctuations in flow, corresponding to daily physiological processes and activity levels within a circadian cycle. Although preliminary, this initial data set may signify that the HeartWare Ò LVAS sensitivity to activity and hemodynamic changes may negate the need to develop an automatic algorithm. Introduction: Sirolimus (SBI) based immunosuppression has been used to slow the progression of renal insufficiency and allograft coronary artery disease in heart transplantation (HT). We hypothesized that SBI improves renal function independent of when it is started post HT Methods: We studied all HT recipients who had undergone conversion from CNI to SBI therapy, and evaluated their outcomes based on time to conversion post HT. They were divided into Early (less than 12 months) and Late (more than 12 months) converters. We assessed significant rejection (3A or 2R), initiation of dialysis and discontinuation of sirolimus. We also evaluated renal function (expressed as serum creatinine) from pre-conversion to 6 months post-conversion in both groups. Results: 16 patients in this series were converted to SBI. Mean age at HT was 49 years (range 22e63). Indications for conversion included arteriopathy 31% (5), renal dysfunction 44 % (7), and MMF intolerance 25% (4). Median starting Sirolimus dose was 2 mg/day and target blood levels were 6e12ng/ml. Mean baseline serum creatinine for all patients was 1.94 6 0.52 mg/dl and for those patients converted for renal dysfunction, 2.73 6 0.48 mg/dl.
Outcomes for Early Vs Late Converters
Outcome Early (n 5 5) Late (n 5 11) Mortality (%) 2 (40) 1 (9) Significant Rejection (%) 2 (40) 3 (27) Dialysis Post-conversion (%) 2 (40) 2 (18) Discontinuation of Sirolimus for adverse effects (%) 0 (0) 3 (27)
At 6 months post-conversion the renal function among the patients converted early showed a negative trend while those converted late had a positive trend regardless of indication for conversion. Mean serum creatinine increased from 1.34 mg/dl to 1.90 mg/dl (p O 0.05) in the early group and decreased from mean of 2.11 mg/dl to 1.47 mg/dl (p O 0.05) in the late group. In addition, there was improvement in renal function among those patients converted for renal dysfunction in both groups; mean serum creatinine decreased from 2.73 6 0.48 mg/dl at baseline to 1.8 6 0.23 mg/dl at 6 months. Conclusion: A strategy for conversion to SBI more than 12 months after HT leads to improved outcomes regardless of indication for change in therapy. Although eligible patients were few, this result is hypothesis generating and could be explored further in larger trials. Purpose: Mortality of subjects with STEMI and cardiogenic shock refractory to maximal therapy including inotropes, pressors, IABP, and early revascularization (ERV) approaches 100%. We have expanded the usual treatment paradigm for such patients with implantation of a biventricular circulatory support system that completely unloads both ventricles. Here we report our early experience with this approach. 
